Loading…
Loading…
LQDA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for LQDA and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for LQDA and 80,000+ other tickers.
See exactly how LQDA's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LQDA and 80,000+ other tickers.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened?
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust disputes. The agreement removes a major source of legal uncertainty surrounding YUTREPIA, Liquidia's inhaled treprostinil treatment for pulmonary arterial hypertension, a condition involving high blood pressure in the lungs.
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.
U.S. stocks were mostly lower, with the Nasdaq Composite falling around 200 points on Wednesday.